The effect of tetracycline fiber therapy on beta-glucuronidase and interleukin-1 beta in crevicular fluid.
Treatment with the tetracycline HCL-containing (Actisite infinity) fiber has been shown to improve clinical measures of periodontitis, as well as reduce the number of sites infected with putative periodontal pathogens. In this study, we examined the effect of the tetracycline fiber on biochemical mediators of the host's inflammatory response in gingival crevicular fluid (GCF). The total amount of the lysosomal enzyme beta-glucuronidase (beta G), considered a marker of primary granule release from polymorphonuclear leukocytes and interleukin-1 beta, a cytokine with important proinflammatory effects, were examined in GCF. Patients with localized recurrent periodontitis were followed over a 16 week period. Treated teeth (Tx), teeth adjacent to treated teeth (ADJ) and control teeth (Cx) were studied. Following fiber therapy, the Tx teeth displayed statistically significant reductions in mean probing depth, depth of the deepest site and bleeding on probing over the 16 weeks of the trial. Significant reduction in the depth of the deepest site was also seen for the ADJ teeth over 16 weeks. Total beta G in GCF was reduced for the Tx teeth comparing baseline to 16 weeks, but no significant changes were observed for the ADJ or Cx teeth. Prior to treatment, total beta G for the Tx teeth was 211 +/- 49 U (mean +/- standard error), versus 146 +/- 174 U for the ADJ teeth and 121 +/- 33 U for the Cx teeth. 16 weeks treatment, the mean values for these 3 categories of teeth were comparable (Tx = 95 +/- 20 U, ADJ = 93 +/- 42 U and Cx = 103 +/- 29 U). For the Tx teeth, the maximum reduction in total beta G following therapy occurred at 6 weeks (65%). Total IL-1 beta was significantly reduced for the Tx teeth at 3 and 6 weeks, but rebounded at 16 weeks. In contrast to what was seen for beta G, the maximum reduction in total IL-1 beta for the Tx teeth was observed at 3 weeks (68%). These data suggest that host mediators associated with increased risk for active disease are reduced following tetracycline fiber therapy. Future studies will determine the relative importance of a reduced microbial challenge versus a tetracycline-mediated direct modification of the host response to account for the reduction in the host inflammatory response in GCF following tetracycline fiber therapy.
Lamster
I B
IB
Division of Periodontics, School of Dental and Oral Surgery, Columbia University, New York, NY 10032, USA.
Pullman
J R
JR
Celenti
R S
RS
Grbic
J T
JT
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003594:Cytoplasmic Granules / Q000201:enzymology; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000737:chemistry* / Q000201:enzymology / Q000276:immunology; D005884:Gingival Hemorrhage / Q000188:drug therapy; D005966:Glucuronidase / Q000032:analysis*; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis; D007375:Interleukin-1 / Q000032:analysis*; D008247:Lysosomes / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000201:enzymology; D010514:Periodontal Pocket / Q000188:drug therapy; D010518:Periodontitis / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology; D012008:Recurrence; D012307:Risk Factors; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D004343:Drug Implants; D018836:Inflammation Mediators; D007375:Interleukin-1; D005966:Glucuronidase; D013752:Tetracycline